Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264714 · ClinicalTrials.gov registry record · Phase 2
Cluster Headache Treatment With Rimegepant
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05264714: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT05264714 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05264714, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05264714
The ClinicalTrials.gov registry entry for NCT05264714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT05264714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05264714 about?
NCT05264714 is a clinical study titled "Cluster Headache Treatment With Rimegepant". The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.
What is the current status of trial NCT05264714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-09-07. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05264714?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT05264714?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.